Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Otorhinolaryngology

  Free Subscription


Articles published in Radiother Oncol

Retrieve available abstracts of 293 articles:
HTML format



Single Articles


    February 2025
  1. ANTUNES J, Young T, Pittock D, Jacobs P, et al
    Assessing multiple MRI sequences in deep learning-based synthetic CT generation for MR-only radiation therapy of head and neck cancers.
    Radiother Oncol. 2025 Feb 8:110782. doi: 10.1016/j.radonc.2025.110782.
    PubMed     Abstract available


  2. VAN DER LAAN HP, Gawryszuk A, van der Schaaf A, Langendijk JA, et al
    Risk reduction of radiation-induced aspiration by sparing specific aspiration-related-organs at risk; an in silico feasibility study.
    Radiother Oncol. 2025;203:110698.
    PubMed     Abstract available


    January 2025
  3. WAN D, Liu Q, Wei JS
    Comment on "Risk factors of level Ib lymph node metastasis and clinical outcome of its selectively prophylactic irradiation in nasopharyngeal carcinoma: A real-world study".
    Radiother Oncol. 2025;205:110767.
    PubMed    


  4. ZHAO C, Miao J
    Response to Dr. Dan Wan, Qing Liu, and Jia-Sha Wei's Letter to the Editor of Radiotherapy and Oncology regarding the paper titled "Comment on "Risk factors of level Ib lymph node metastasis and clinical outcome of its selectively prophylactic irradiat
    Radiother Oncol. 2025 Jan 30:110768. doi: 10.1016/j.radonc.2025.110768.
    PubMed    


  5. ZHONG J, Chen H, Chen X, Ma N, et al
    Identifying adverse nodal features associated with poor prognosis in stage IB nasopharyngeal carcinoma patients based on the 9th AJCC/UICC staging system: Implications for treatment intensification.
    Radiother Oncol. 2025;205:110747.
    PubMed     Abstract available


  6. NEH H, de Vette SPM, Stoffers RH, Zhou G, et al
    Normal tissue complication probability model predicting taste impairment in head and neck cancer patients: Evaluating the taste bud bearing tongue mucosa as a predictor.
    Radiother Oncol. 2025 Jan 28:110746. doi: 10.1016/j.radonc.2025.110746.
    PubMed     Abstract available


  7. TORAIH E, Hussein M, Elshazli R, Abdelmaksoud A, et al
    Therapeutic outcomes and safety of radiofrequency ablation for primary papillary thyroid carcinoma: A game-changing meta-analysis.
    Radiother Oncol. 2025;205:110706.
    PubMed     Abstract available


  8. RAJENDRAN P, Yang Y, Niedermayr TR, Gensheimer M, et al
    Large language model-augmented learning for auto-delineation of treatment targets in head-and-neck cancer radiotherapy.
    Radiother Oncol. 2025;205:110740.
    PubMed     Abstract available


  9. NERICH V, Falcoz A, Nadin L, Meurisse A, et al
    Cost-minimization analysis of the GORTEC 2014-04 randomized phase II study of stereotactic ablative radiotherapy (SABR) or chemotherapy-SABR in oligometastatic head and neck cancer.
    Radiother Oncol. 2025;204:110726.
    PubMed     Abstract available


  10. CHEN L, Li J, Li K, Hu J, et al
    Corrigendum to "Evaluation and analysis of risk factors of hearing impairment for nasopharyngeal carcinoma treated using intensity-modulated radiotherapy" [Radiother. Oncol. 190 (2024) 109985].
    Radiother Oncol. 2025;204:110719.
    PubMed    


  11. LU T, Gao X, Yu Z, Liu L, et al
    Reducing radiation-induced hypothyroidism by modified delineation of cervical lymphatic drainage area for nasopharyngeal carcinoma treated by intensity-modulated radiation Therapy: 3 years' experience.
    Radiother Oncol. 2025;204:110713.
    PubMed     Abstract available


  12. KAMPEL L, Feldstein S, Tsuriel S, Trejo LL, et al
    TP53 genetic heterogeneity in recurrent or second primary head and neck squamous cell carcinoma.
    Radiother Oncol. 2025;204:110714.
    PubMed     Abstract available


  13. MENG X, Ju Z, Sakai M, Li Y, et al
    Normal tissue complication probability model for acute oral mucositis in patients with head and neck cancer undergoing carbon ion radiation therapy based on dosimetry, radiomics, and dosiomics.
    Radiother Oncol. 2025;204:110709.
    PubMed     Abstract available


  14. ZHANG L, Zhang Z, Wang Y, Zhu Y, et al
    Evaluation of machine learning models for predicting xerostomia in adults with head and neck cancer during proton and heavy ion radiotherapy.
    Radiother Oncol. 2025;204:110712.
    PubMed     Abstract available


  15. LIU Y, Chen Z, Zhou Q, Shang X, et al
    A feasibility study of dose-band prediction in radiation therapy: Predicting a spectrum of plan dose.
    Radiother Oncol. 2025;202:110593.
    PubMed     Abstract available


    December 2024
  16. WINTER RM, Boeke S, Leibfarth S, Habrich J, et al
    Clinical validation of a prognostic preclinical magnetic resonance imaging biomarker for radiotherapy outcome in head-and-neck cancer.
    Radiother Oncol. 2024;204:110702.
    PubMed     Abstract available


  17. RUHLE A, Weymann M, Behrens M, Olbrich J, et al
    Predicting cisplatin tolerability in older adults with head and neck cancer - Insights for improved chemoradiation outcomes.
    Radiother Oncol. 2024 Dec 24:110697. doi: 10.1016/j.radonc.2024.110697.
    PubMed     Abstract available


  18. GIRAUD P, Guihard S, Thureau S, Guilbert P, et al
    Prediction of the need of enteral nutrition during radiation therapy for head and neck cancers.
    Radiother Oncol. 2024 Dec 21:110693. doi: 10.1016/j.radonc.2024.110693.
    PubMed     Abstract available


  19. HE SQ, Liu GY, Yu YH, Wang L, et al
    Efficacy of local-regional radiotherapy in de novo metastatic nasopharyngeal carcinoma patients receiving chemo-immunotherapy: A multicenter, propensity score matching study.
    Radiother Oncol. 2024 Dec 19:110687. doi: 10.1016/j.radonc.2024.110687.
    PubMed     Abstract available


  20. ZHANG S, Yan L, Li R, Zhao Y, et al
    Development and validation of a nomogram to predict overall survival in patients with External auditory canal cancer.
    Radiother Oncol. 2024 Dec 19:110691. doi: 10.1016/j.radonc.2024.110691.
    PubMed     Abstract available


  21. HUANG X, Lin K, Chen W, Zhang D, et al
    Modulation of the local angiotensin II: Augmentation of ferroptosis and radiosensitivity in nasopharyngeal carcinoma via the HIF-1alpha-HILPDA axis.
    Radiother Oncol. 2024 Dec 19:110686. doi: 10.1016/j.radonc.2024.110686.
    PubMed     Abstract available


  22. KOCH A, Reinhardt P, Elicin O, Aebersold DM, et al
    Predictive biomarkers of radiotherapy- related dermatitis, xerostomia, mucositis and dysphagia in head and neck cancer: A systematic review.
    Radiother Oncol. 2024 Dec 18:110689. doi: 10.1016/j.radonc.2024.110689.
    PubMed     Abstract available


  23. LIANG JL, Wen YF, Huang YP, Guo J, et al
    A prognostic and predictive model based on deep learning to identify optimal candidates for intensity-modulated radiotherapy alone in patients with stage II nasopharyngeal carcinoma: A retrospective multicenter study.
    Radiother Oncol. 2024;203:110660.
    PubMed     Abstract available


  24. LI R, Zhao Y, Wu K, Li H, et al
    p16 status or response to induction chemotherapy, which predicts survival outcomes in Chinese oropharyngeal cancer treated with definitive radiotherapy?
    Radiother Oncol. 2024;201:110578.
    PubMed     Abstract available


    November 2024
  25. MALLICK S
    Response to "Optimizing palliative radiation: Beyond dose escalation in advanced head and neck squamous cell carcinoma".
    Radiother Oncol. 2024;202:110656.
    PubMed    


  26. SHI X, Hui B, Wang Y, Lu Y, et al
    Optimizing palliative radiation: Beyond dose escalation in advanced head and neck squamous cell carcinoma.
    Radiother Oncol. 2024 Nov 29:110655. doi: 10.1016/j.radonc.2024.110655.
    PubMed    


  27. JIMENEZ-LABAIG P, Aymerich C, Rullan A, Cacicedo J, et al
    Prevalence of depressive and anxiety symptoms in patients with head and neck cancer undergoing radiotherapy: A systematic review and meta-analysis of longitudinal studies.
    Radiother Oncol. 2024;202:110649.
    PubMed     Abstract available


  28. WU CN, Wang JD, Chen WC, Lin CY, et al
    Intensity-modulated proton therapy versus volumetric-modulated ARC therapy in patients with nasopharyngeal carcinoma: A long-term, multicenter cohort study.
    Radiother Oncol. 2024 Nov 23:110648. doi: 10.1016/j.radonc.2024.110648.
    PubMed     Abstract available


  29. LIU M, Pang B, Chen S, Zeng Y, et al
    Deep learning-based multiple-CT optimization: An adaptive treatment planning approach to account for anatomical changes in intensity-modulated proton therapy for head and neck cancers.
    Radiother Oncol. 2024;202:110650.
    PubMed     Abstract available


  30. URSINO S, Malfatti G, Felice F, Bonomo P, et al
    Deglutition preservation after swallowing (Swoars)-sparing IMRT in head and neck cancers: Definitive results of A multicenter prospective study of the italian association of radiotherapy and clinical oncology (Airo).
    Radiother Oncol. 2024 Nov 22:110651. doi: 10.1016/j.radonc.2024.110651.
    PubMed     Abstract available


  31. HUANG LW, Pan JW, Li B, Wu WX, et al
    Evaluation of radiation induced brain injury in nasopharyngeal carcinoma patients based on multi-parameter quantitative MRI: A prospective longitudinal study.
    Radiother Oncol. 2024 Nov 11:110621. doi: 10.1016/j.radonc.2024.110621.
    PubMed     Abstract available


  32. ZHU MY, Wu HJ, Fang T, Zhang GS, et al
    Risk factors of level Ib lymph node metastasis and clinical outcome of its selectively prophylactic irradiation in nasopharyngeal carcinoma: A real-world study.
    Radiother Oncol. 2024 Nov 11:110620. doi: 10.1016/j.radonc.2024.110620.
    PubMed     Abstract available


  33. MALLICK S, Dagar A, Ghosh A, Aashita, et al
    Optimum radiation dose for palliation in head and neck squamous cell carcinoma (OpRAH) - A phase 3 randomized controlled trial.
    Radiother Oncol. 2024 Nov 8:110611. doi: 10.1016/j.radonc.2024.110611.
    PubMed     Abstract available


  34. DE LEEUW ALMP, Giralt J, Tao Y, Benavente S, et al
    Protocol compliance in a multicentric phase III trial investigating scheduled adaptive radiotherapy and dose painting in head and neck cancer.
    Radiother Oncol. 2024 Nov 8:110612. doi: 10.1016/j.radonc.2024.110612.
    PubMed     Abstract available


  35. VAN BRUGGEN IG, van Dijk M, Brinkman-Akker MJ, Lofman F, et al
    Clinical implementation of deep learning robust IMPT planning in oropharyngeal cancer patients: A blinded clinical study.
    Radiother Oncol. 2024;200:110522.
    PubMed     Abstract available


  36. YANG WC, Koto M, Ikawa H, Imai R, et al
    Clinical target volume design and dose in carbon-ion radiation therapy for sinonasal mucosal melanoma.
    Radiother Oncol. 2024;200:110511.
    PubMed     Abstract available


  37. XU MH, Dou JP, Guo MH, Yi WQ, et al
    Risk factors for recurrent laryngeal nerve injury in microwave ablation of thyroid nodules: A multicenter study.
    Radiother Oncol. 2024;200:110516.
    PubMed     Abstract available


  38. CHEN AM
    De-escalated radiation for human papillomavirus virus-related oropharyngeal cancer: Who, why, what, where, when, how, how much...and what next?
    Radiother Oncol. 2024;200:110373.
    PubMed     Abstract available


  39. CHEN B, Zhan Z, Xu Y, Yu S, et al
    Long-term trends in the burden of nasopharyngeal carcinoma in China: A comprehensive analysis from 1990 to 2021 and projections to 2030 based on the global burden of disease study 2021.
    Radiother Oncol. 2024 Nov 1:110613. doi: 10.1016/j.radonc.2024.110613.
    PubMed     Abstract available


    October 2024
  40. TATTENBERG S, Shin J, Hoehr C, Sung W, et al
    Correlation of dynamic blood dose with clinical outcomes in radiotherapy for head-and-neck cancer.
    Radiother Oncol. 2024 Oct 29:110603. doi: 10.1016/j.radonc.2024.110603.
    PubMed     Abstract available


  41. GAITO S, Hwang E, Thwaites D, Ahern V, et al
    Identifying paediatric patients at risk of severe hearing impairment after treatment for malignancies of the H&N/CNS with proton therapy.
    Radiother Oncol. 2024 Oct 26:110597. doi: 10.1016/j.radonc.2024.110597.
    PubMed     Abstract available


  42. FELDMAN J, Pryanichnikov A, Shwartz D, Hillman Y, et al
    Study of upright patient positioning reproducibility in image-guided proton therapy for head and neck cancers.
    Radiother Oncol. 2024;201:110572.
    PubMed     Abstract available


  43. LIANG Z, Luo C, Li S, Zhu Y, et al
    Guiding induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma with ternary classification of predicted individual treatment effect.
    Radiother Oncol. 2024 Oct 9:110571. doi: 10.1016/j.radonc.2024.110571.
    PubMed     Abstract available


  44. PAN J, Qiu Z, Fu G, Liang J, et al
    Non-complete recovery of temporal lobe white matter diffusion metrics at one year Post-Radiotherapy: Implications for Radiation-Induced necrosis risk.
    Radiother Oncol. 2024;199:110420.
    PubMed     Abstract available


    September 2024
  45. THIRUVENGADAM R, Kim SH, Thiruvengadam M
    Fructose 1,6-bisphosphate aldolase: A promising prognostic marker for oral cancer and its role in radiotherapy response.
    Radiother Oncol. 2024;200:110537.
    PubMed     Abstract available


  46. DAVE J
    Concerns regarding the use of only phase 2 study to Justify palliative radiotherapy vs. Palliative chemo-radiotherapy in unresectable head and neck cancer.
    Radiother Oncol. 2024;200:110526.
    PubMed    


  47. KONG W, Huiskes M, Habraken SJM, Astreinidou E, et al
    Reducing the lateral dose penumbra in IMPT by incorporating transmission pencil beams.
    Radiother Oncol. 2024;198:110388.
    PubMed     Abstract available


    August 2024
  48. YANG Y, Shao R, Cao X, Chen M, et al
    Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable esophageal squamous cell carcinoma: A pooled analysis of randomized clinical trials.
    Radiother Oncol. 2024;200:110517.
    PubMed     Abstract available


  49. ZHU WY, Huang J, Lu ZQ, Yang S, et al
    Management of post-radiation carotid blowout syndrome in patients with head and neck cancer: A systematic review.
    Radiother Oncol. 2024;200:110502.
    PubMed     Abstract available


  50. CHEN L, Wang H, Chen W, Li K, et al
    Induction plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy in elderly patients with locoregionally advanced nasopharyngeal carcinoma.
    Radiother Oncol. 2024 Aug 25:110497. doi: 10.1016/j.radonc.2024.110497.
    PubMed     Abstract available


  51. REINEMA FV, Hudson N, Adema GJ, Peeters WJM, et al
    MitoTam induces ferroptosis and increases radiosensitivity in head and neck cancer cells.
    Radiother Oncol. 2024;200:110503.
    PubMed     Abstract available


  52. BEUKEMA JC, Haveman JW, Langendijk JA, Oldehinkel E, et al
    Blood biomarkers for cardiac damage during and after radiotherapy for esophageal cancer: A prospective cohort study.
    Radiother Oncol. 2024;200:110479.
    PubMed     Abstract available


  53. TOPKAN E, Somay E, Selek U
    Comment on: Re-irradiation versus systemic therapy for the management of local-regionally recurrent head and neck cancer.
    Radiother Oncol. 2024;199:110467.
    PubMed    


  54. MA B, Guo J, De Biase A, van Dijk LV, et al
    PET/CT based transformer model for multi-outcome prediction in oropharyngeal cancer.
    Radiother Oncol. 2024;197:110368.
    PubMed     Abstract available


    July 2024
  55. SATO M, Hirose K
    A simple prediction model for the risk of boron neutron capture therapy-induced nausea and vomiting in head and neck cancer.
    Radiother Oncol. 2024;199:110464.
    PubMed     Abstract available


  56. MENESES AG, Ferreira EB, Vieira LAC, Bontempo PSM, et al
    Comparison of liposomal gel with and without addition of chamomile for prevention of radiation dermatitis in head and neck cancer patients: A randomized controlled trial.
    Radiother Oncol. 2024;199:110440.
    PubMed     Abstract available


  57. XIE C, Yu X, Tan N, Zhang J, et al
    Combined deep learning and radiomics in pretreatment radiation esophagitis prediction for patients with esophageal cancer underwent volumetric modulated arc therapy.
    Radiother Oncol. 2024;199:110438.
    PubMed     Abstract available


  58. ZUKAUSKAITE R, Kristensen MH, Eriksen JG, Johansen J, et al
    Comparison of 3-year local control using DAHANCA radiotherapy guidelines before and after implementation of five millimetres geometrical GTV to high-dose CTV margin.
    Radiother Oncol. 2024;196:110284.
    PubMed     Abstract available


  59. CHIANG CL, Chan KSK, Li H, Ng WT, et al
    Using the genomic adjusted radiation dose (GARD) to personalize the radiation dose in nasopharyngeal cancer.
    Radiother Oncol. 2024;196:110287.
    PubMed     Abstract available


  60. FITZGERALD KT, Lyons C, England A, McEntee MF, et al
    Response to letter to the editor by Somay et al., re: "Risk factors associated with the development of osteoradionecrosis (ORN) in head and neck cancer patients in Ireland: A 10-year retrospective review".
    Radiother Oncol. 2024 Jul 1:110412. doi: 10.1016/j.radonc.2024.110412.
    PubMed    


    June 2024
  61. NAVRAN A, Kayembe MT, Gouw ZAR, Vogel WV, et al
    FGD-PET/CT three months after (chemo)radiotherapy for head and neck squamous cell carcinoma spares considerable number of patients from a salvage neck dissection.
    Radiother Oncol. 2024;198:110407.
    PubMed     Abstract available


  62. TOPKAN E, Somay E, Selek U
    Letter to the editor regarding "Risk factors associated with the development of osteoradionecrosis (ORN) in head and neck cancer patients in Ireland: A 10-year retrospective review".
    Radiother Oncol. 2024 Jun 25:110411. doi: 10.1016/j.radonc.2024.110411.
    PubMed    


  63. CANTERS R, van der Klugt K, Trier Taasti V, Buijsen J, et al
    Robustness of intensity modulated proton treatment of esophageal cancer for anatomical changes and breathing motion.
    Radiother Oncol. 2024 Jun 23:110409. doi: 10.1016/j.radonc.2024.110409.
    PubMed     Abstract available


  64. SATO M, Hirose K
    Efficacy and safety of boron neutron capture therapy for Hypopharyngeal/Laryngeal cancer patients with previous head and neck irradiation in Japan.
    Radiother Oncol. 2024 Jun 14:110382. doi: 10.1016/j.radonc.2024.110382.
    PubMed     Abstract available


  65. MOORE-PALHARES D, Saifuddin M, Dasgupta A, Anzola Pena ML, et al
    Radiation enhancement using focussed ultrasound-stimulated microbubbles for head and neck cancer: A phase 1 clinical trial.
    Radiother Oncol. 2024;198:110380.
    PubMed     Abstract available


  66. ZHOU H, Zhao Q, Huang W, Liang Z, et al
    A novel fully automatic segmentation and counting system for metastatic lymph nodes on multimodal magnetic resonance Imaging: Evaluation and prognostic implications in Nasopharyngeal carcinoma.
    Radiother Oncol. 2024 Jun 2:110367. doi: 10.1016/j.radonc.2024.110367.
    PubMed     Abstract available


  67. LIU YC, Zhang X, Yang HN, Zhang L, et al
    Proposals for the delineation of neck clinical target volume for definitive Radiation therapy in patients with oral/ oropharyngeal squamous cell cancer based on lymph node distribution.
    Radiother Oncol. 2024;195:110225.
    PubMed     Abstract available


    May 2024
  68. JOSE BESSO M, Bitto V, Koi L, Wijaya Hadiwikarta W, et al
    Transcriptomic and epigenetic landscape of nimorazole-enhanced radiochemotherapy in head and neck cancer.
    Radiother Oncol. 2024 May 30:110348. doi: 10.1016/j.radonc.2024.110348.
    PubMed     Abstract available


  69. GEHIN W, Chastagner P, Mansuy L, Bernier-Chastagner V, et al
    Dosimetric analysis of hearing loss after cranial radiation therapy in children: A single-institution study from the french national registry pediart.
    Radiother Oncol. 2024 May 26:110346. doi: 10.1016/j.radonc.2024.110346.
    PubMed     Abstract available


  70. SONG J, Yang X, Wu J, Wu Z, et al
    The association analysis between fatigue and body composition loss in patients with nasopharyngeal carcinoma during radiotherapy: An observational longitudinal study.
    Radiother Oncol. 2024 May 24:110340. doi: 10.1016/j.radonc.2024.110340.
    PubMed     Abstract available


  71. ZHANG L, Jin S, Wang Y, Zhang Z, et al
    Predict nutrition-related adverse outcomes in head and neck cancer patients undergoing radiotherapy: A systematic review.
    Radiother Oncol. 2024 May 23:110339. doi: 10.1016/j.radonc.2024.110339.
    PubMed     Abstract available


  72. NIELSEN CP, Lorenzen EL, Jensen K, Eriksen JG, et al
    Interobserver variation in organs at risk contouring in head and neck cancer according to the DAHANCA guidelines.
    Radiother Oncol. 2024;197:110337.
    PubMed    


  73. BOREL C, Sun XS, Coutte A, Bera G, et al
    Standard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: Results of the CisFRad (GORTEC 2015-02) randomized phase II trial.
    Radiother Oncol. 2024;197:110329.
    PubMed     Abstract available


  74. ZHANG WW, Guo R
    Response to "Comments on 'Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study'".
    Radiother Oncol. 2024 May 11:110327. doi: 10.1016/j.radonc.2024.110327.
    PubMed    


  75. ZHAN ZJ, Huang HY, Xiao YH, Zhao YP, et al
    Anxiety and depression in nasopharyngeal carcinoma patients and network analysis to identify central symptoms: A cross-sectional study from a high-incidence area.
    Radiother Oncol. 2024 May 10:110324. doi: 10.1016/j.radonc.2024.110324.
    PubMed     Abstract available


  76. SHEN M, Lin X, Yang C, Zhou Z, et al
    Potential predictive value of IVIM MR for xerostomia in nasopharyngeal carcinoma.
    Radiother Oncol. 2024 May 9:110323. doi: 10.1016/j.radonc.2024.110323.
    PubMed     Abstract available


  77. SMITS HJG, Raaijmakers CPJ, de Ridder M, Gouw ZAR, et al
    Improved delineation with diffusion weighted imaging for laryngeal and hypopharyngeal tumors validated with pathology.
    Radiother Oncol. 2024;194:110182.
    PubMed     Abstract available


    April 2024
  78. XU L, Liu S, Yang Y, Shu L, et al
    LINC00313 suppresses autophagy and promotes stemness of nasopharyngeal carcinoma cells through PTBP1/STIM1 axis.
    Radiother Oncol. 2024;196:110310.
    PubMed     Abstract available


  79. LIU Y, Ma J, Zeng XY, Zuo ZC, et al
    Efficacy of metastatic lesion radiotherapy in patients with metastatic nasopharyngeal carcinoma: A multicenter retrospective study.
    Radiother Oncol. 2024;196:110311.
    PubMed     Abstract available


  80. STARUCH M, Speth MM, Neyer P, Riesterer O, et al
    Radiation-associated changes in saliva composition of head and neck cancer patients: A systematic review.
    Radiother Oncol. 2024 Apr 20:110279. doi: 10.1016/j.radonc.2024.110279.
    PubMed     Abstract available


  81. SELENGE BEDUK ESEN C, Nur Can G, Akkus Yildirim B
    Comments on "Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study".
    Radiother Oncol. 2024 Apr 20:110292. doi: 10.1016/j.radonc.2024.110292.
    PubMed    


  82. FITZGERALD KT, Lyons C, England A, McEntee MF, et al
    Risk factors associated with the development of osteoradionecrosis (ORN) in Head and Neck cancer patients in Ireland: A 10-year retrospective review.
    Radiother Oncol. 2024 Apr 17:110286. doi: 10.1016/j.radonc.2024.110286.
    PubMed     Abstract available


  83. ZHENG Z, Shen Y, Su J, Ji X, et al
    Assessing radiation-induced carotid artery injury using ultrasound in patients with head and neck cancer.
    Radiother Oncol. 2024 Apr 17:110285. doi: 10.1016/j.radonc.2024.110285.
    PubMed     Abstract available


  84. CHEN AM, Harris JP, Nabar R, Tjoa T, et al
    Re-irradiation versus systemic therapy for the management of local-regionally recurrent head and neck cancer.
    Radiother Oncol. 2024 Apr 16:110278. doi: 10.1016/j.radonc.2024.110278.
    PubMed     Abstract available


  85. DE LEEUW ALMP, Giralt J, Tao Y, Benavente S, et al
    A multicentric randomized controlled phase III trial of adaptive and 18F-FDG-PET-guided dose-redistribution in locally advanced head and neck squamous cell carcinoma (ARTFORCE).
    Radiother Oncol. 2024 Apr 16:110281. doi: 10.1016/j.radonc.2024.110281.
    PubMed     Abstract available


  86. SHUANG H, Feng J, Caineng C, Qifeng J, et al
    Long-term efficacy analysis of radiotherapy and local management of metastases in patients with newly diagnosed oligometastatic nasopharyngeal carcinoma: A prospective, single-arm, single-center clinical study.
    Radiother Oncol. 2024 Apr 5:110265. doi: 10.1016/j.radonc.2024.110265.
    PubMed     Abstract available


  87. CHOW JCH, Lee J, Lai MMP, Li S, et al
    Multi-domain neurocognitive impairment following definitive intensity-modulated radiotherapy for nasopharyngeal cancer: A cross-sectional study.
    Radiother Oncol. 2024;193:110143.
    PubMed     Abstract available


    March 2024
  88. DONG J, Ng WT, Wong CHL, Li JS, et al
    Dosimetric parameters predict radiation-induced temporal lobe necrosis in nasopharyngeal carcinoma patients: A systematic review and meta-analysis.
    Radiother Oncol. 2024 Mar 25:110258. doi: 10.1016/j.radonc.2024.110258.
    PubMed     Abstract available


  89. HUYNH TM, Falk RS, Hellebust TP, Dale E, et al
    Chronic fatigue in long-term survivors of head and neck cancer treated with radiotherapy.
    Radiother Oncol. 2024;195:110231.
    PubMed     Abstract available


  90. BERTHOLET J, Mackeprang PH, Loebner HA, Mueller S, et al
    Organs-at-risk dose and normal tissue complication probability with dynamic trajectory radiotherapy (DTRT) for head and neck cancer.
    Radiother Oncol. 2024 Mar 19:110237. doi: 10.1016/j.radonc.2024.110237.
    PubMed     Abstract available


  91. BOON CS, Ramkumar S, Boon IS
    Proton beam radiotherapy head and neck cancer study design and endpoints.
    Radiother Oncol. 2024 Mar 16:110234. doi: 10.1016/j.radonc.2024.110234.
    PubMed    


  92. KOUTROUMPAKIS E, Mohamed ASR, Chaftari P, Rosenthal DI, et al
    Longitudinal changes in the carotid arteries of head and neck cancer patients following radiation therapy: Results from a prospective serial imaging biomarker characterization study.
    Radiother Oncol. 2024 Mar 9:110220. doi: 10.1016/j.radonc.2024.110220.
    PubMed     Abstract available


  93. CHOW JCH, Ho JCS, Man Cheung K, Johnson D, et al
    Neurological complications of modern radiotherapy for head and neck cancer.
    Radiother Oncol. 2024 Mar 2:110200. doi: 10.1016/j.radonc.2024.110200.
    PubMed     Abstract available


  94. CARSUZAA F, Chary E, Thariat J, Dufour X, et al
    Obstructive sleep apnea syndrome: A frequent and difficult-to-detect complication of radiotherapy for oropharyngeal cancers.
    Radiother Oncol. 2024;192:110109.
    PubMed     Abstract available


  95. ZHANG WW, Lin JY, Wang GY, Huang CL, et al
    Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study.
    Radiother Oncol. 2024;194:110189.
    PubMed     Abstract available


    February 2024
  96. POPULAIRE P, Defraene G, Haustermans K
    Letter to the editor regarding "External validation of a lung cancer-based prediction model for two-year mortality in esophageal cancer patient cohorts" by M. Berbee et al.
    Radiother Oncol. 2024 Feb 28:110175. doi: 10.1016/j.radonc.2024.110175.
    PubMed    


  97. KOTO M, Ikawa H, Inaniwa T, Imai R, et al
    Dose-averaged LET optimized carbon-ion radiotherapy for head and neck cancers.
    Radiother Oncol. 2024;194:110180.
    PubMed     Abstract available


  98. BERBEE M, Muijs CT, Schuit E
    Response to letter to the editor regarding "External validation of a lung cancer-based prediction model for two-year mortality in esophageal cancer patient cohorts" by M. Berbee et al.
    Radiother Oncol. 2024 Feb 17:110176. doi: 10.1016/j.radonc.2024.110176.
    PubMed    


  99. FIORINO C, Palumbo D, Mori M, Palazzo G, et al
    Early regression index (ERI) on MR images as response predictor in esophageal cancer treated with neoadjuvant chemo-radiotherapy: Interim analysis of the prospective ESCAPE trial.
    Radiother Oncol. 2024;194:110160.
    PubMed     Abstract available


  100. WANG X, Huang N, Yip PL, Wang J, et al
    The individualized delineation of clinical target volume for primary nasopharyngeal carcinoma based on invasion risk of substructures: A prospective, real-word study with a large population.
    Radiother Oncol. 2024;194:110154.
    PubMed     Abstract available


  101. HORSHOLT KRISTENSEN M, Kristina Sorensen M, Tramm T, Alsner J, et al
    Tumor volume and cancer stem cell expression as prognostic markers for high-dose loco-regional failure in head and neck squamous cell carcinoma - a DAHANCA 19 study.
    Radiother Oncol. 2024 Feb 8:110149. doi: 10.1016/j.radonc.2024.110149.
    PubMed     Abstract available


  102. PERRIER L, Balusson F, Morelle M, Castelli J, et al
    Cost-effectiveness of weekly adaptive radiotherapy versus standard IMRT in head and neck cancer alongside the ARTIX trial.
    Radiother Oncol. 2024;193:110116.
    PubMed     Abstract available


    January 2024
  103. FRANK MH, van Dijk BAC, Schoonbeek RC, Zindler J, et al
    Differences in the association of time to treatment initiation and survival according to various head and neck cancer sites in a nationwide cohort.
    Radiother Oncol. 2024 Jan 21:110107. doi: 10.1016/j.radonc.2024.110107.
    PubMed     Abstract available


  104. BLITZER GC, Paz C, Glassey A, Ganz OR, et al
    Functionality of Bone Marrow Mesenchymal Stromal Cells Derived from Head and Neck Cancer Patients - A FDA-IND Enabling Study Regarding MSC-based Treatments for Radiation-Induced Xerostomia.
    Radiother Oncol. 2024 Jan 13:110093. doi: 10.1016/j.radonc.2024.110093.
    PubMed     Abstract available


  105. PIERIK AS, Poell JB, Brink A, Stigter-van Walsum M, et al
    Intratumor genetic heterogeneity and head and neck cancer relapse.
    Radiother Oncol. 2024 Jan 5:110087. doi: 10.1016/j.radonc.2024.110087.
    PubMed     Abstract available


  106. WANG F, Zhou L, Zhang LJ, Xie CB, et al
    Concurrent chemoradiotherapy versus radiotherapy alone in older patients with stage II Nasopharyngeal Carcinoma after Intensity-Modulated Radiotherapy: a propensity score-matched cohort study.
    Radiother Oncol. 2024 Jan 5:110081. doi: 10.1016/j.radonc.2024.110081.
    PubMed     Abstract available


  107. GUO Q, Lu T, Huang W, Xu H, et al
    Selectively sparing of the supraclavicular area during intensity-modulated radiotherapy in nasopharyngeal carcinoma: A double-center observation study.
    Radiother Oncol. 2024 Jan 4:110086. doi: 10.1016/j.radonc.2024.110086.
    PubMed     Abstract available


  108. VERDUIJN GM, Sijtsema ND, van Norden Y, Heemsbergen WD, et al
    Response to the letter-to-the-editor "Comments on: Accounting for fractionation and heterogeneous dose distributions in the modelling of osteoradionecrosis in oropharyngeal carcinoma treatment".
    Radiother Oncol. 2024;190:110036.
    PubMed    


  109. SOMAY E, Yilmaz B, Topkan E
    Comments on "Accounting for fractionation and heterogeneous dose distributions in the modelling of osteoradionecrosis in oropharyngeal carcinoma treatment".
    Radiother Oncol. 2024;190:110035.
    PubMed    


  110. ZHU Y, Cheng J, Li Y, Pan D, et al
    Progression of cognitive dysfunction in NPC survivors with radiation-induced brain necrosis: A prospective cohort.
    Radiother Oncol. 2024;190:110033.
    PubMed     Abstract available


    December 2023
  111. MURDAUGH DL, Milner D, Cardenas CE, Heinzman KA, et al
    Volumetric Brain Assessment of Long-Term Head and Neck Cancer Survivors.
    Radiother Oncol. 2023 Dec 22:110068. doi: 10.1016/j.radonc.2023.110068.
    PubMed     Abstract available


  112. LIN CY, Chang CL, Lin KC, Chen WM, et al
    Statin Use Reduces Radiation-Induced Stroke Risk in Advanced Nasopharyngeal Carcinoma Patients.
    Radiother Oncol. 2023 Dec 22:110067. doi: 10.1016/j.radonc.2023.110067.
    PubMed     Abstract available


  113. YU-CHEN, Luo MJ, Liu RP, Jin J, et al
    Phase I dose-escalation study of nab-paclitaxel combined with cisplatin and capecitabin as induction chemotherapy followed by concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma.
    Radiother Oncol. 2023 Dec 20:110051. doi: 10.1016/j.radonc.2023.110051.
    PubMed     Abstract available


  114. AI QYH, King AD, Yuan H, Vardhanabhuti V, et al
    Radiologic extranodal extension for nodal staging in nasopharyngeal carcinoma.
    Radiother Oncol. 2023 Dec 13:110050. doi: 10.1016/j.radonc.2023.110050.
    PubMed     Abstract available


  115. BIRD D, Speight R, Andersson S, Wingqvist J, et al
    Deep learning MRI-only synthetic-CT generation for pelvis, brain and head and neck cancers.
    Radiother Oncol. 2023 Dec 12:110052. doi: 10.1016/j.radonc.2023.110052.
    PubMed     Abstract available


  116. HABRICH J, Boeke S, Fritz V, Koerner E, et al
    Reproducibility of diffusion-weighted magnetic resonance imaging in head and neck cancer assessed on a 1.5 T MR-Linac and comparison to parallel measurements on a 3 T diagnostic scanner.
    Radiother Oncol. 2023 Dec 7:110046. doi: 10.1016/j.radonc.2023.110046.
    PubMed     Abstract available


  117. MARIA HUYNH TT, Dale E, Sorum Falk R, Paulsen Hellebust T, et al
    Radiation-induced long-term dysphagia in survivors of head and neck cancer and association with dose-volume parameters.
    Radiother Oncol. 2023 Dec 5:110044. doi: 10.1016/j.radonc.2023.110044.
    PubMed     Abstract available


  118. HOU Z, Guo Y, Shen X, Dong B, et al
    Treatment options for stage III-N2 pulmonary lymphoepithelioma-like carcinoma: A retrospective cohort study.
    Radiother Oncol. 2023;189:109937.
    PubMed     Abstract available


    November 2023
  119. MENG Z, Li P, Yang D, Huang H, et al
    The feasibility of level Ib-sparing intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma and high-risk factors classified based on the International Guideline.
    Radiother Oncol. 2023 Nov 24:110027. doi: 10.1016/j.radonc.2023.110027.
    PubMed     Abstract available


  120. SOMAY E, Topkan E, Selek U
    Comment on: The extent of unnecessary tooth loss due to extractions prior to radiotherapy based on radiation field and dose in patients with head and neck cancer.
    Radiother Oncol. 2023 Nov 24:110025. doi: 10.1016/j.radonc.2023.110025.
    PubMed    


  121. BUURMAN DJM, Speksnijder CM, Granzier ME, Timmer VCML, et al
    Response to: Comment on: The extent of unnecessary tooth loss due to extractions prior to radiotherapy based on radiation field and dose in patients with head and neck cancer.
    Radiother Oncol. 2023 Nov 24:110026. doi: 10.1016/j.radonc.2023.110026.
    PubMed    


  122. DELERUE C, Pasquier D, Bogart E, Mirabel X, et al
    Stereotactic reirradiation in the treatment of head and neck cancers: A retrospective study on the long-term experience of the Oscar Lambret Center.
    Radiother Oncol. 2023;190:110029.
    PubMed     Abstract available


  123. HUANG CL, Wang GY, Lou JH, Chen L, et al
    Oral chemotherapy versus observation alone in nasopharyngeal carcinoma patients with persistently detected circulating cell-free Epstein-Barr virus DNA during follow-up.
    Radiother Oncol. 2023;190:110032.
    PubMed     Abstract available


  124. BERBEE M, Muijs CT, Voncken FEM, Wee LS, et al
    External validation of a lung cancer-based prediction model for two-year mortality in esophageal cancer patient cohorts.
    Radiother Oncol. 2023 Nov 8:109979. doi: 10.1016/j.radonc.2023.109979.
    PubMed     Abstract available


  125. HR M, P P, L H, Ds M, et al
    PROton versus photon Therapy for Esophageal Cancer - a Trimodality strategy (PROTECT) NCT050555648.
    Radiother Oncol. 2023 Nov 5:109980. doi: 10.1016/j.radonc.2023.109980.
    PubMed    


  126. CHEN L, Li J, Li K, Hu J, et al
    Evaluation and Analysis of Risk Factors of Hearing Impairment for Nasopharyngeal Carcinoma treated using Intensity-Modulated Radiotherapy.
    Radiother Oncol. 2023 Nov 3:109985. doi: 10.1016/j.radonc.2023.109985.
    PubMed     Abstract available


  127. KIM K, Oh D, Myoung Noh J, Won Min Y, et al
    Outcomes Following Hypofractionated Radiation Therapy Alone for Surgically Unfit Early Esophageal Squamous Cell Carcinoma Patients; A Retrospective Single Center Analysis.
    Radiother Oncol. 2023 Nov 3:109982. doi: 10.1016/j.radonc.2023.109982.
    PubMed     Abstract available


  128. VERDUIJN GM, Sijtsema ND, van Norden Y, Heemsbergen WD, et al
    Accounting for fractionation and heterogeneous dose distributions in the modelling of osteoradionecrosis in oropharyngeal carcinoma treatment.
    Radiother Oncol. 2023;188:109889.
    PubMed     Abstract available


    October 2023
  129. HE YQ, Wang TM, Yang DW, Xue WQ, et al
    A comprehensive predictive model for radiation-induced brain injury in risk stratification and personalized radiotherapy of nasopharyngeal carcinoma.
    Radiother Oncol. 2023 Oct 30:109974. doi: 10.1016/j.radonc.2023.109974.
    PubMed     Abstract available


  130. AMSTUTZ F, Krcek R, Bachtiary B, Weber DC, et al
    Treatment planning comparison for head and neck cancer between photon, proton, and combined proton-photon therapy - from a fixed beam line to an arc.
    Radiother Oncol. 2023 Oct 30:109973. doi: 10.1016/j.radonc.2023.109973.
    PubMed     Abstract available


  131. CHANG CL, Lin KC, Chen WM, Shia BC, et al
    Comparing the Oncologic Outcomes of Proton Therapy and Intensity-Modulated Radiation Therapy for Head and Neck Squamous Cell Carcinoma.
    Radiother Oncol. 2023 Oct 28:109971. doi: 10.1016/j.radonc.2023.109971.
    PubMed     Abstract available


  132. FRIBORG J, Jensen K, Eriksen JG, Samsoe E, et al
    Considerations for study design in the DAHANCA 35 trial of protons versus photons for head and neck cancer.
    Radiother Oncol. 2023 Oct 21:109958. doi: 10.1016/j.radonc.2023.109958.
    PubMed     Abstract available


  133. CHEN AM
    Management of Unknown Primary Head and Neck Cancer with Radiation Therapy in the Era of Human Papillomavirus (HPV): No Longer Cutting Down the Tree to Get an Apple.
    Radiother Oncol. 2023 Oct 14:109952. doi: 10.1016/j.radonc.2023.109952.
    PubMed     Abstract available


  134. GAI X, Su L, Huang S, Zeng J, et al
    Correlation between hippocampal radiation doses and psychological condition for patients with stage T1-2 nasopharyngeal carcinoma.
    Radiother Oncol. 2023 Oct 7:109942. doi: 10.1016/j.radonc.2023.109942.
    PubMed     Abstract available


  135. LI S, Zhang W, Liang B, Huang W, et al
    A Rulefit-Based Prognostic Analysis Using Structured MRI Report to Select Potential Beneficiaries from Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma: A Dual-Centre Study.
    Radiother Oncol. 2023 Oct 7:109943. doi: 10.1016/j.radonc.2023.109943.
    PubMed     Abstract available


  136. LIN CH, Yan JL, Yap WK, Kang CJ, et al
    Prognostic Value of Interim CT-based Peritumoral and Intratumoral Radiomics in Laryngeal and Hypopharyngeal Cancer Patients Undergoing Definitive Radiotherapy.
    Radiother Oncol. 2023 Oct 6:109938. doi: 10.1016/j.radonc.2023.109938.
    PubMed     Abstract available


  137. SUN XS, Wang JW, Han F, Zou RH, et al
    Prognostic value of metastatic cervical lymph node stiffness in nasopharyngeal carcinoma: A prospective cohort study.
    Radiother Oncol. 2023 Oct 6:109939. doi: 10.1016/j.radonc.2023.109939.
    PubMed     Abstract available


    September 2023
  138. YEONG SONG J, Sung Ho M, Suh YG, Kim JH, et al
    Definitive radiotherapy in patients with clinical T1N0M0 esophageal squamous cell carcinoma: a multicenter retrospective study (KROG 21-10).
    Radiother Oncol. 2023 Sep 30:109936. doi: 10.1016/j.radonc.2023.109936.
    PubMed     Abstract available


  139. BOLLEN H, Gulyban A, Nuyts S
    Impact of consensus guidelines on delineation of primary tumor Clinical Target Volume (CTVp) for head and neck cancer: results of a national review project.
    Radiother Oncol. 2023 Sep 20:109915. doi: 10.1016/j.radonc.2023.109915.
    PubMed     Abstract available


  140. LIU S, Zou Y, Zhong M, Li T, et al
    Prognostic Significance of MRI-Defined Sarcopenia in Patients with Nasopharyngeal Carcinoma: A Propensity Score Matched Analysis of Real-World Data.
    Radiother Oncol. 2023 Sep 5:109904. doi: 10.1016/j.radonc.2023.109904.
    PubMed     Abstract available


  141. YAN W, Liu T, He M, Yi J, et al
    Induction chemotherapy plus re-irradiation versus re-irradiation alone in locally recurrent nasopharyngeal carcinoma: A model-based analysis.
    Radiother Oncol. 2023 Sep 5:109903. doi: 10.1016/j.radonc.2023.109903.
    PubMed     Abstract available


  142. ADRIAN G, Forslund O, Pedersen L, Sjovall J, et al
    Circulating tumour HPV16 DNA quantification - A prognostic tool for progression-free survival in patients with HPV-related oropharyngeal carcinoma receiving curative chemoradiotherapy.
    Radiother Oncol. 2023;186:109773.
    PubMed     Abstract available


  143. SIJTSEMA ND, Verduijn GM, Nasserinejad K, van Norden Y, et al
    Development of a local dose-response relationship for osteoradionecrosis within the mandible.
    Radiother Oncol. 2023;186:109736.
    PubMed     Abstract available


  144. LI D, Yang LN, Lin JY, Wu YZ, et al
    Eosinophil Dynamics During Chemo-Radiotherapy Correlate to Clinical Outcome in Stage ?-?a Nasopharyngeal Carcinoma Patients: Results from A Large Cohort Study.
    Radiother Oncol. 2023 Sep 1:109900. doi: 10.1016/j.radonc.2023.109900.
    PubMed     Abstract available


    August 2023
  145. OZER O, Shafi H, O'Reilly D, Loiseau C, et al
    Need for standardization in the use of structures in the intensity-modulated radiation therapy planning of head and neck cancers, a GORTEC study.
    Radiother Oncol. 2023 Aug 31:109895. doi: 10.1016/j.radonc.2023.109895.
    PubMed     Abstract available


  146. DING X, Cui X, Cui X, Wang S, et al
    Efficacy and toxicities of elective upper-neck irradiation versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: a meta-analysis.
    Radiother Oncol. 2023 Aug 23:109860. doi: 10.1016/j.radonc.2023.109860.
    PubMed     Abstract available


  147. ROESCH J, Ruhle A, Nicolay NH, Hecht M, et al
    Reply to the comment on "Dose-escalated re-irradiation improves outcome in locally recurrent head and neck cancer - Results of a large multicenter analysis'' by Kahvecioglu et al.
    Radiother Oncol. 2023 Aug 22:109866. doi: 10.1016/j.radonc.2023.109866.
    PubMed    


  148. IYIZOBA-EBOZUE Z, Prestwich R, Brown S, Hall E, et al
    Neurocognitive function following (chemo)radiotherapy for nasopharyngeal cancer and other head and neck cancers: a systematic review.
    Radiother Oncol. 2023 Aug 22:109863. doi: 10.1016/j.radonc.2023.109863.
    PubMed     Abstract available


  149. KATSUTA T, Murakami Y, Kawahara D, Miyoshi S, et al
    Novel Simulation for Dosimetry Impact of Diaphragm Respiratory Motion in Four-Dimensional Volumetric Modulated Arc Therapy for Esophageal Cancer.
    Radiother Oncol. 2023 Aug 8:109849. doi: 10.1016/j.radonc.2023.109849.
    PubMed     Abstract available


  150. BUURMAN DJM, Speksnijder CM, Granzier ME, C M L Timmer V, et al
    The extent of unnecessary tooth loss due to extractions prior to radiotherapy based on radiation field and dose in patients with head and neck cancer.
    Radiother Oncol. 2023 Aug 3:109847. doi: 10.1016/j.radonc.2023.109847.
    PubMed     Abstract available


  151. KOTEVSKI DP, Vajdic CM, Field M, Smee RI, et al
    Inter-hospital variation in data collection, radiotherapy treatment, and survival in patients with head and neck cancer: a multisite study.
    Radiother Oncol. 2023 Aug 3:109843. doi: 10.1016/j.radonc.2023.109843.
    PubMed     Abstract available


  152. DIAS GOMES DA SILVA N, Sergio da Silva Santos P, Carolina Magalhaes A, Afonso Rabelo Buzalaf M, et al
    Antibacterial, antibiofilm and anticaries effect of BioXtra(R) mouthrinse for head and neck cancer (HNC) patients under a microcosm biofilm model.
    Radiother Oncol. 2023 Aug 3:109846. doi: 10.1016/j.radonc.2023.109846.
    PubMed     Abstract available


    July 2023
  153. LIU J, Zhang B, Su Y, Qin G, et al
    Hypofractionated Radiotherapy compared with Conventionally Fractionated Radiotherapy to treat Initial Distant Metastases in Nasopharyngeal Carcinoma: A Multicenter, prospective, randomized, Phase II Trial.
    Radiother Oncol. 2023 Jul 20:109815. doi: 10.1016/j.radonc.2023.109815.
    PubMed     Abstract available


  154. HANSEN CR, Jensen K, Smulders B, Holm AIS, et al
    Evaluation of decentralised model-based selection of head and neck cancer patients for a proton treatment study. DAHANCA 35.
    Radiother Oncol. 2023 Jul 19:109812. doi: 10.1016/j.radonc.2023.109812.
    PubMed     Abstract available


  155. KAHVECIOGLU A, Yuce Sari S, Yazici G
    Comments on ''Dose-escalated Re-irradiation Improves Outcome in Locally Recurrent Head and Neck Cancer - Results of a Large Multicenter Analysis''.
    Radiother Oncol. 2023 Jul 17:109809. doi: 10.1016/j.radonc.2023.109809.
    PubMed    


  156. LIN C, Lu N, Liang JL, Guo J, et al
    Clinical treatment considerations in the intensity-modulated radiotherapy era for parotid lymph node metastasis in patients with nasopharyngeal carcinoma.
    Radiother Oncol. 2023 Jul 7:109802. doi: 10.1016/j.radonc.2023.109802.
    PubMed     Abstract available


  157. CONTI A
    In regard to: "Dosimetric predictive factors for facial nerve paralysis after Cyberknife stereotactic radiotherapy for vestibular schwannomas: A single institution experience of 88 patients".
    Radiother Oncol. 2023 Jul 6:109796. doi: 10.1016/j.radonc.2023.109796.
    PubMed    


  158. GEHIN W, Lassalle B, Salleron J, Anxionnat R, et al
    Response to the letter-to-the-editor "In regard to: Dosimetric predictive factors for facial nerve paralysis after Cyberknife stereotactic radiotherapy for vestibular schwannomas: A single institution experience of 88 patients".
    Radiother Oncol. 2023 Jul 6:109797. doi: 10.1016/j.radonc.2023.109797.
    PubMed    


  159. WEISS Y, Chin L, Younas E, Guo K, et al
    Cine MRI-based Analysis of Intrafractional Motion in Radiation Treatment Planning of Head and Neck Cancer Patients.
    Radiother Oncol. 2023 Jul 4:109790. doi: 10.1016/j.radonc.2023.109790.
    PubMed     Abstract available


  160. LIN P, Holloway L, Min M, Lee M, et al
    Prognostic and predictive values of baseline and mid-treatment FDG-PET in oropharyngeal carcinoma treated with primary definitive (chemo)radiation and impact of HPV status: Review of current literature and emerging roles.
    Radiother Oncol. 2023;184:109686.
    PubMed     Abstract available


  161. DE JONG BA, Korevaar EW, Maring A, Werkman CI, et al
    Proton arc therapy increases the benefit of proton therapy for oropharyngeal cancer patients in the model based clinic.
    Radiother Oncol. 2023;184:109670.
    PubMed     Abstract available


  162. ZHOU J, Wu J, Wu G, Huang J, et al
    TBX18 knockdown sensitizes esophageal squamous cell carcinoma to radiotherapy by blocking the CHN1/RhoA axis.
    Radiother Oncol. 2023 Jul 1:109788. doi: 10.1016/j.radonc.2023.109788.
    PubMed     Abstract available


    June 2023
  163. KJEMS J, Elisabet Hakansson K, Andrup Kristensen C, Grau Eriksen J, et al
    The influence of tumor volume on the risk of distant metastases in head and neck squamous cell carcinomas.
    Radiother Oncol. 2023 Jun 27:109771. doi: 10.1016/j.radonc.2023.109771.
    PubMed     Abstract available


  164. LIN X, Guo Z, Lin S, Qiu Y, et al
    Transcriptional expression of radiation-induced early cortical morphological alterations and its association with radiation necrosis in patients with nasopharyngeal carcinoma.
    Radiother Oncol. 2023 Jun 27:109770. doi: 10.1016/j.radonc.2023.109770.
    PubMed     Abstract available


  165. GAN Y, Langendijk JA, van der Schaaf A, van den Bosch L, et al
    An efficient strategy to select head and neck cancer patients for adaptive radiotherapy.
    Radiother Oncol. 2023 Jun 21:109763. doi: 10.1016/j.radonc.2023.109763.
    PubMed     Abstract available


  166. YANG Q, Xia L, Feng LF, Gong WJ, et al
    Multi-trajectories of health-related quality of life and their associated factors in patients with nasopharyngeal carcinoma: A longitudinal study.
    Radiother Oncol. 2023 Jun 12:109743. doi: 10.1016/j.radonc.2023.109743.
    PubMed     Abstract available


  167. ROJO-SANTIAGO J, Korevaar E, Perko Z, Both S, et al
    PTV-based VMAT vs. robust IMPT for Head-and-Neck Cancer: A probabilistic uncertainty analysis of clinical plan evaluation with the Dutch model-based selection.
    Radiother Oncol. 2023 Jun 8:109729. doi: 10.1016/j.radonc.2023.109729.
    PubMed    


  168. CAMPO F, Iocca O, De Virgilio A, Mazzola F, et al
    Treatment of oropharyngeal squamous cell carcinoma: Is swallowing quality better after TORS or RT?
    Radiother Oncol. 2023;183:109547.
    PubMed     Abstract available


    May 2023
  169. KONG FF, Pan GS, Du CR, Ni MS, et al
    Prognostic value of circulating Epstein-Barr virus DNA level post-induction chemotherapy for patients with nasopharyngeal carcinoma: a recursive partitioning risk stratification analysis.
    Radiother Oncol. 2023 May 25:109721. doi: 10.1016/j.radonc.2023.109721.
    PubMed     Abstract available


  170. MCDONALD BA, Salzillo T, Mulder S, Ahmed S, et al
    Prospective Evaluation of In Vivo and Phantom Repeatability and Reproducibility of Diffusion-Weighted MRI Sequences on 1.5T MRI-Linear Accelerator (MR-Linac) and MR Simulator Devices for Head and Neck Cancers.
    Radiother Oncol. 2023 May 19:109717. doi: 10.1016/j.radonc.2023.109717.
    PubMed     Abstract available


  171. LU T, Xu H, Huang W, Zong J, et al
    Constructing an Individualized Surveillance Framework for Nasopharyngeal Carcinoma Based on a Dynamic Risk-adapted Approach.
    Radiother Oncol. 2023 May 17:109716. doi: 10.1016/j.radonc.2023.109716.
    PubMed     Abstract available


  172. MORAL NAKAMURA D, da Graca Pinto H, Baena Elchin C, Thomazotti Berard L, et al
    Efficacy of bethanechol chloride in the treatment of radiation-induced xerostomia in patients with head and neck cancer: a systematic review and meta-analysis.
    Radiother Oncol. 2023 May 17:109715. doi: 10.1016/j.radonc.2023.109715.
    PubMed     Abstract available


  173. LU J, Qin Z, Li N, Ma J, et al
    High-dose versus standard-dose radiotherapy in concurrent chemoradiotherapy for inoperable esophageal cancer: a systematic review and meta-analysis.
    Radiother Oncol. 2023 May 9:109700. doi: 10.1016/j.radonc.2023.109700.
    PubMed     Abstract available


  174. FENG ZONG J, Lin PJ, Tsou HH, Guo Q, et al
    Comparison the Acute Toxicity of Two Different Induction Chemotherapy Schedules with Cisplatin and Fluorouracil in Nasopharyngeal Carcinoma Patients.
    Radiother Oncol. 2023 May 9:109699. doi: 10.1016/j.radonc.2023.109699.
    PubMed     Abstract available


    April 2023
  175. ZHAO DW, Teng F, Meng LL, Fan WJ, et al
    Development and validation of a nomogram for prediction of recovery from moderate-severe xerostomia post-radiotherapy in nasopharyngeal carcinoma patients.
    Radiother Oncol. 2023 Apr 27:109683. doi: 10.1016/j.radonc.2023.109683.
    PubMed     Abstract available


  176. PAN Z, Men K, Liang B, Song Z, et al
    A subregion-based prediction model for local-regional recurrence risk in head and neck squamous cell carcinoma.
    Radiother Oncol. 2023 Apr 27:109684. doi: 10.1016/j.radonc.2023.109684.
    PubMed     Abstract available


  177. ZHAO W, Ke S, Cai X, Zuo Z, et al
    Radiotherapy plus camrelizumaband irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase II trial.
    Radiother Oncol. 2023 Apr 25:109679. doi: 10.1016/j.radonc.2023.109679.
    PubMed     Abstract available


  178. A C FIAGAN Y, Bossuyt E, Nevens D, Machiels M, et al
    The use of in-vivo dosimetry to identify head and neck cancer patients needing adaptive radiotherapy.
    Radiother Oncol. 2023 Apr 19:109676. doi: 10.1016/j.radonc.2023.109676.
    PubMed     Abstract available


    March 2023
  179. BOLOGNA M, Corino V, Cavalieri S, Calareso G, et al
    Prognostic radiomic signature for head and neck cancer: development and validation on a multi-centric MRI dataset.
    Radiother Oncol. 2023 Mar 31:109638. doi: 10.1016/j.radonc.2023.109638.
    PubMed     Abstract available


  180. MENECEUR S, Lock S, Gudziol V, Hering S, et al
    Corrigendum to "Residual gammaH2AX foci in head and neck squamous cell carcinomas as predictors for tumour radiosensitivity: Evaluation in pre-clinical xenograft models and clinical specimens" [Radiother. Oncol. 137 (2019) 24-31].
    Radiother Oncol. 2023;183:109619.
    PubMed    


  181. S R MOHAMED A, Abusaif A, He R, Wahid K, et al
    Prospective validation of diffusion-weighted MRI as a biomarker of tumor response and oncologic outcomes in head and neck cancer: Results from an observational biomarker pre-qualification study.
    Radiother Oncol. 2023 Mar 27:109641. doi: 10.1016/j.radonc.2023.109641.
    PubMed     Abstract available


  182. LU ZJ, Liu T, Lin JY, Pei ST, et al
    Identifying the prognostic value of MRI-based tumor response and predicting the risk of radio-resistance in re-radiotherapy for locally recurrent nasopharyngeal carcinoma.
    Radiother Oncol. 2023 Mar 22:109635. doi: 10.1016/j.radonc.2023.109635.
    PubMed     Abstract available


  183. ALY F, Ronn Hansen C, Al Mouiee D, Sundaresan P, et al
    Outcome prediction models incorporating clinical variables for Head and Neck Squamous cell Carcinoma: a systematic review of methodological conduct and risk of bias.
    Radiother Oncol. 2023 Mar 17:109629. doi: 10.1016/j.radonc.2023.109629.
    PubMed    


  184. DUBEC MJ, Buckley DL, Berks M, Clough A, et al
    First-in-Human Technique Translation of Oxygen-Enhanced MRI to an MR Linac System in Patients with Head and Neck Cancer.
    Radiother Oncol. 2023 Mar 2:109592. doi: 10.1016/j.radonc.2023.109592.
    PubMed     Abstract available


  185. WU Z, Qi B, Lin FF, Zhang L, et al
    Characteristics of local extension based on tumor distribution in nasopharyngeal carcinoma and proposed clinical target volume delineation.
    Radiother Oncol. 2023 Mar 2:109595. doi: 10.1016/j.radonc.2023.109595.
    PubMed     Abstract available


  186. WANG JH, Salama V, McCoy L, Dede C, et al
    Dysphagia and shortness-of-breath as markers for treatment failure and survival in oropharyngeal cancer after radiation.
    Radiother Oncol. 2023;180:109465.
    PubMed     Abstract available


    February 2023
  187. TAN W, Mao M, He H, Chen M, et al
    Endonasopharyngeal Ultrasound and Magnetic Resonance Imaging Features of Recurrent Retropharyngeal Nodes in Nasopharyngeal Carcinoma Patients: A Radiologic-histopathologic Study.
    Radiother Oncol. 2023 Feb 24:109579. doi: 10.1016/j.radonc.2023.109579.
    PubMed     Abstract available


  188. BOLLEN H, Willems S, Wegge M, Maes F, et al
    Benefits of automated gross tumor volume segmentation in head and neck cancer using multi-modality information.
    Radiother Oncol. 2023 Feb 21:109574. doi: 10.1016/j.radonc.2023.109574.
    PubMed     Abstract available


  189. ZHANG J, Lam SK, Teng X, Ma Z, et al
    Radiomic Feature Repeatability and Its Impact on Prognostic Model Generalizability: A Multi-Institutional Study on Nasopharyngeal Carcinoma Patients.
    Radiother Oncol. 2023 Feb 21:109578. doi: 10.1016/j.radonc.2023.109578.
    PubMed     Abstract available


  190. VALENTINI C, Ebert N, Koi L, Pfeifer M, et al
    Preclinical trial comparing radiotherapy alone versus standard radiochemotherapy in three human papilloma virus (HPV) negative and three HPV-positive head and neck squamous cell carcinoma (HNSCC) xenograft tumour models.
    Radiother Oncol. 2023 Feb 20:109546. doi: 10.1016/j.radonc.2023.109546.
    PubMed     Abstract available


  191. BEYAN C, Beyan E
    The prognosis may not be determined with the use of some pre-treatment complete blood count values in patients with non-metastatic nasopharyngeal carcinoma.
    Radiother Oncol. 2023 Feb 9:109529. doi: 10.1016/j.radonc.2023.109529.
    PubMed    


  192. MAO JR, Lan KQ, Liu SL, Liu C, et al
    In reply to the Letter to the Editor by Cengiz Beyan and Esin Beyan regarding ''Can the prognosis of individual patients with nasopharyngeal carcinoma be predicted using a routine blood test at admission?".
    Radiother Oncol. 2023 Feb 9:109530. doi: 10.1016/j.radonc.2023.109530.
    PubMed    


  193. PATRICIA KAPLAN L, Ivalu Sander Holm A, Grau Eriksen J, Heijmen BJM, et al
    Patient anatomy-specific trade-offs between sub-clinical disease coverage and normal tissue dose reduction in head-and-neck cancer.
    Radiother Oncol. 2023 Feb 8:109526. doi: 10.1016/j.radonc.2023.109526.
    PubMed     Abstract available


  194. GEHIN W, Lassalle B, Salleron J, Anxionnat R, et al
    DOSIMETRIC PREDICTIVE FACTORS FOR FACIAL NERVE PARALYSIS AFTER CYBERKNIFE(R) STEREOTACTIC RADIOTHERAPY FOR VESTIBULAR SCHWANNOMAS: A SINGLE INSTITUTION EXPERIENCE OF 88 PATIENTS.
    Radiother Oncol. 2023 Feb 1:109519. doi: 10.1016/j.radonc.2023.109519.
    PubMed     Abstract available


    January 2023
  195. YAO JJ, Jin YN, Zhang WJ, Zhang HY, et al
    Response to the letter by Dr Sari regarding the article "The feasibility of reduced-dose radiotherapy in childhood nasopharyngeal carcinoma with favorable response to neoadjuvant chemotherapy".
    Radiother Oncol. 2023 Jan 31:109487. doi: 10.1016/j.radonc.2023.109487.
    PubMed    


  196. TERZIDIS E, Friborg J, Vogelius I, Lelkaitis G, et al
    Tumor volume definitions in head and neck squamous cell carcinoma - comparing PET/MRI and histopathology.
    Radiother Oncol. 2023 Jan 20:109484. doi: 10.1016/j.radonc.2023.109484.
    PubMed     Abstract available


  197. YE X, Liu J, Quan R, Lu Y, et al
    DKK1 Affects Survival of Patients with Head and Neck Squamous Cell Carcinoma by Inducing Resistance to Radiotherapy and Immunotherapy.
    Radiother Oncol. 2023 Jan 20:109485. doi: 10.1016/j.radonc.2023.109485.
    PubMed     Abstract available


  198. LUO X, Liao W, He Y, Tang F, et al
    Deep learning-based accurate delineation of primary gross tumor volume of nasopharyngeal carcinoma on heterogeneous magnetic resonance imaging: a large-scale and multi-center study.
    Radiother Oncol. 2023 Jan 16:109480. doi: 10.1016/j.radonc.2023.109480.
    PubMed     Abstract available


  199. WANG X, Bai H, Li R, Wang L, et al
    High versus Standard Radiation Dose of Definitive Concurrent Chemoradiotherapy for Esophageal Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Radiother Oncol. 2023 Jan 12:109463. doi: 10.1016/j.radonc.2023.109463.
    PubMed     Abstract available


  200. LI Y, Sijtsema NM, de Vette SPM, Steenbakkers RJHM, et al
    Validation of the (18)F-FDG PET image biomarker model predicting late xerostomia after head and neck cancer radiotherapy.
    Radiother Oncol. 2023 Jan 3:109458. doi: 10.1016/j.radonc.2022.109458.
    PubMed     Abstract available


  201. GUEVORGUIAN P, Chinnery T, Lang P, Nichols A, et al
    External validation of a CT-based radiomics signature in oropharyngeal cancer: Assessing sources of variation.
    Radiother Oncol. 2023;178:109434.
    PubMed     Abstract available


    December 2022
  202. LEEUWENBERG AM, Reitsma JB, Bosch LVD, Hoogland J, et al
    The relation between prediction model performance measures and patient selection outcomes for proton therapy in head and neck cancer.
    Radiother Oncol. 2022 Dec 22:109449. doi: 10.1016/j.radonc.2022.109449.
    PubMed     Abstract available


  203. HUANG X, Zhuang M, Yang S, Wang Y, et al
    The valuable role of dynamic (18)F FDG PET/CT-derived kinetic parameter K(i) in patients with nasopharyngeal carcinoma prior to radiotherapy: a prospective study.
    Radiother Oncol. 2022 Dec 22:109440. doi: 10.1016/j.radonc.2022.109440.
    PubMed     Abstract available


  204. MAO JR, Lan KQ, Liu SL, Liu C, et al
    Can the prognosis of individual patients with nasopharyngeal carcinoma be predicted using a routine blood test at admission?
    Radiother Oncol. 2022 Dec 22:109445. doi: 10.1016/j.radonc.2022.109445.
    PubMed     Abstract available


  205. LIU Y, Zhang Y, Wang J, Huang X, et al
    Caudal distribution pattern of metastatic neck lymph nodes in nasopharyngeal carcinoma and prognostic significance of nodal spread distances.
    Radiother Oncol. 2022 Dec 19:109443. doi: 10.1016/j.radonc.2022.109443.
    PubMed     Abstract available


  206. ZHU GL, Zhang XM, Yang KB, Tang LL, et al
    Metastatic patterns of level II-V cervical lymph nodes assessed per vertebral levels in nasopharyngeal carcinoma.
    Radiother Oncol. 2022 Dec 19:109447. doi: 10.1016/j.radonc.2022.109447.
    PubMed     Abstract available


  207. ZENG GP, Sun R, Zhao Z
    Letter to the editor regarding "The dosimetric and clinical advantages of the GTV-CTV-PTV margins reduction by 6mm in head and neck squamous cell carcinoma: Significant acute and late toxicity reduction".
    Radiother Oncol. 2022 Dec 14:109442. doi: 10.1016/j.radonc.2022.109442.
    PubMed    


  208. HU YJ, Lu TZ, Guo QJ, Zhang L, et al
    The role of radiologic extranodal extension in predicting prognosis and chemotherapy benefit for T1-2N1 nasopharyngeal carcinoma: a multicenter retrospective study.
    Radiother Oncol. 2022 Dec 1:S0167-8140(22)04582.
    PubMed     Abstract available


  209. DE FELICE F, Cirillo A, Botticelli A
    Ideal regimen for induction chemotherapy in nasopharyngeal cancer: Still a hot issue?
    Radiother Oncol. 2022;177:111-112.
    PubMed    


    November 2022
  210. CHEN WY, Lu SH, Wang YM, Wang CW, et al
    Post-irradiation Sarcoma after Definitive Radiation Therapy for Nasopharyngeal Carcinoma.
    Radiother Oncol. 2022 Nov 23:S0167-8140(22)04560.
    PubMed     Abstract available


  211. LIU ZC, Zeng KH, Gu ZB, Chen RP, et al
    Comparison of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in Lymph-Node-Stage Nasopharyngeal Carcinoma based on propensity score-matching.
    Radiother Oncol. 2022 Nov 18:S0167-8140(22)04554.
    PubMed     Abstract available


  212. WANG G, Huang C, Yang K, Guo R, et al
    Neck level Ib-sparing versus level Ib-irradiation in intensity-modulated radiotherapy for the treatment of nasopharyngeal carcinoma with high-risk factors: A propensity score-matched cohort study.
    Radiother Oncol. 2022 Nov 11. pii: S0167-8140(22)04548.
    PubMed     Abstract available


  213. YAO JJ, Jin YN, Lin YJ, Zhang WJ, et al
    The feasibility of reduced-dose radiotherapy in childhood nasopharyngeal carcinoma with favorable response to neoadjuvant chemotherapy.
    Radiother Oncol. 2022 Nov 11. pii: S0167-8140(22)04547.
    PubMed     Abstract available


  214. BIN Y, Meng Z, Huang LL, Hu XY, et al
    Prognostic value of the cervical lymph node necrosis ratio in nasopharyngeal carcinoma.
    Radiother Oncol. 2022 Nov 11. pii: S0167-8140(22)04549.
    PubMed     Abstract available


  215. TAKADA A, Ichikawa Y, Nakamura S, Toyomasu Y, et al
    Preliminary results of reduced myocardial blood flow in the subacute phase after radiation therapy for thoracic esophageal cancer: A quantitative analysis with stress dynamic myocardial computed tomography perfusion imaging.
    Radiother Oncol. 2022 Nov 10. pii: S0167-8140(22)04546.
    PubMed    


  216. ZHONG Z, Wang D, Liu Y, Shao S, et al
    Lymph Drainage and Cervical Fascia Anatomy-Oriented Differential Nodal CTV Delineation at the Supraclavicular Region for Esophageal Cancer and Nasopharyngeal Cancer.
    Radiother Oncol. 2022 Nov 3. pii: S0167-8140(22)04531.
    PubMed    


  217. CHOW JCH, Lui JCF, Cheung KM, Tam AHP, et al
    Post-radiation primary hypothyroidism in patients with head and neck cancer: External validation of thyroid gland dose-volume constraints with long-term endocrine outcomes.
    Radiother Oncol. 2022 Nov 3. pii: S0167-8140(22)04529.
    PubMed     Abstract available


  218. HUANG H, Miao J, Zhao C, Wang L, et al
    Response to Gargi S Sarode, Sachin C Sarode, and Rahul Anand's Letter to the Editor of Radiotherapy and Oncology regarding the paper titled "Impact on xerostomia for nasopharyngeal carcinoma patients treated with superficial parotid lobe-sparing inten
    Radiother Oncol. 2022 Nov 2. pii: S0167-8140(22)04517.
    PubMed    


  219. SARODE GS, Sarode SC, Anand R
    Letter to the Editor of Radiotherapy and Oncology regarding the paper titled "Impact on xerostomia for nasopharyngeal carcinoma patients treated with superficial parotid lobe-sparing intensity-modulated radiation therapy (SPLS-IMRT): A prospective pha
    Radiother Oncol. 2022 Nov 2. pii: S0167-8140(22)04515.
    PubMed    


  220. LEE CT, Litwin S, Yao CMKL, Liu JC, et al
    Osteoradionecrosis rate in oropharynx cancer treated with dose volume histogram based constraints.
    Radiother Oncol. 2022;176:215-221.
    PubMed     Abstract available


  221. VAN DER WEIJST L, Azria D, Berkovic P, Boisselier P, et al
    The correlation between pre-treatment symptoms, acute and late toxicity and patient-reported health-related quality of life in non-small cell lung cancer patients: Results of the REQUITE study.
    Radiother Oncol. 2022;176:127-137.
    PubMed     Abstract available


    October 2022
  222. ROESCH J, Oertel M, Wegen S, Trommer M, et al
    Dose-escalated re-irradiation improves outcome in locally recurrent head and neck cancer - Results of a large multicenter analysis.
    Radiother Oncol. 2022 Oct 20. pii: S0167-8140(22)04502.
    PubMed     Abstract available


  223. TIEN CT, Chen CN, Young YH
    Post-irradiation endolymphatic hydrops vs. post-irradiation sudden deafness.
    Radiother Oncol. 2022 Oct 17. pii: S0167-8140(22)04504.
    PubMed     Abstract available


  224. RONN HANSEN C, Price G, Field M, Sarup N, et al
    Larynx cancer survival model developed through open-source federated learning.
    Radiother Oncol. 2022 Oct 5. pii: S0167-8140(22)04493.
    PubMed     Abstract available


    September 2022
  225. NADERI E, Schack LMH, Welsh C, Sim AYL, et al
    Meta-GWAS identifies the heritability of acute radiation-induced toxicities in head and neck cancer.
    Radiother Oncol. 2022 Sep 30. pii: S0167-8140(22)04486.
    PubMed     Abstract available


  226. HUMBERT-VIDAN L, Hansen CR, Fuller CD, Petit S, et al
    Protocol Letter: A multi-institutional retrospective case-control cohort investigating PREDiction models for Mandibular OsteoRadioNecrosis in head and neck cancer (PREDMORN).
    Radiother Oncol. 2022 Sep 27. pii: S0167-8140(22)04473.
    PubMed    


  227. DRAGUET C, Barragan-Montero AM, Chocan Vera M, Thomas M, et al
    Automated clinical decision support system with deep learning dose prediction and NTCP models to evaluate treatment complications in patients with esophageal cancer.
    Radiother Oncol. 2022 Sep 24. pii: S0167-8140(22)04263.
    PubMed     Abstract available


  228. OUD M, Breedveld S, Gizynska M, Kroesen M, et al
    An online adaptive plan library approach for intensity modulated proton therapy for head and neck cancer.
    Radiother Oncol. 2022 Sep 20. pii: S0167-8140(22)04278.
    PubMed     Abstract available


    August 2022
  229. DE ROEST RH, van der Heijden M, W R Wesseling F, de Ruiter EJ, et al
    Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer.
    Radiother Oncol. 2022 Aug 13. pii: S0167-8140(22)04234.
    PubMed     Abstract available


  230. ZHANG Y, Alshaikhi J, Amos RA, Lowe M, et al
    Improving workflow for adaptive proton therapy with predictive anatomical modelling: A proof of concept.
    Radiother Oncol. 2022;173:93-101.
    PubMed     Abstract available


    July 2022
  231. GHATASHEH H, Hui Huang S, Su J, Xu W, et al
    Evaluation of risk-tailored individualized selection of radiation therapy target volume for Head and Neck Carcinoma of Unknown Primary.
    Radiother Oncol. 2022 Jul 26. pii: S0167-8140(22)04214.
    PubMed     Abstract available


  232. HABRICH J, Boeke S, Nachbar M, Nikolaou K, et al
    Repeatability of diffusion-weighted magnetic resonance imaging in head and neck cancer at a 1.5 T MR-Linac.
    Radiother Oncol. 2022 Jul 25. pii: S0167-8140(22)04218.
    PubMed     Abstract available


  233. HUANG H, Miao J, Xiao X, Hu J, et al
    Impact on xerostomia for nasopharyngeal carcinoma patients treated with superficial parotid lobe-sparing intensity-modulated radiation therapy (SPLS-IMRT): a prospective phase II randomized controlled study.
    Radiother Oncol. 2022 Jul 8. pii: S0167-8140(22)04191.
    PubMed     Abstract available


  234. PRICE JM, West CM, Dixon LM, Iyizoba-Ebozue Z, et al
    Similar long-term swallowing outcomes for accelerated, mildly-hypofractionated radiotherapy compared to conventional fractionation in oropharyngeal cancer: A multi-centre study.
    Radiother Oncol. 2022;172:111-117.
    PubMed     Abstract available


    June 2022
  235. QIAN D, Chen X, Shang X, Wang Y, et al
    Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery in patients with locally advanced esophageal squamous cell carcinoma who achieved clinical complete response when induction chemoradiation finished: A phase II rando
    Radiother Oncol. 2022 Jun 25. pii: S0167-8140(22)04176.
    PubMed     Abstract available


  236. KROESE TE, Christ SM, van Rossum PSN, Burger MDL, et al
    Incidence and survival of patients with oligometastatic esophagogastric cancer: a multicenter cohort study.
    Radiother Oncol. 2022 Jun 23. pii: S0167-8140(22)04173.
    PubMed     Abstract available


  237. GONG J, Zhang W, Huang W, Liao Y, et al
    CT-based radiomics nomogram may predict local recurrence-free survival in esophageal cancer patients receiving definitive chemoradiation or radiotherapy: a multicenter study.
    Radiother Oncol. 2022 Jun 21. pii: S0167-8140(22)04171.
    PubMed     Abstract available


  238. HANSEN CR, Price G, Field M, Sarup N, et al
    Open-source distributed learning validation for a larynx cancer survival model following radiotherapy.
    Radiother Oncol. 2022 Jun 20. pii: S0167-8140(22)04170.
    PubMed     Abstract available


  239. FU G, Xie Y, Pan J, Qiu Y, et al
    Longitudinal study of irradiation-induced brain functional network alterations in patients with nasopharyngeal carcinoma.
    Radiother Oncol. 2022 Jun 16. pii: S0167-8140(22)04164.
    PubMed     Abstract available


  240. SCHOONBEEK RC, Festen S, van der Laan BFAM, Plaat BEC, et al
    The effect of delayed treatment initiation on adverse events and recurrence in older head and neck cancer patients.
    Radiother Oncol. 2022 Jun 6. pii: S0167-8140(22)04146.
    PubMed     Abstract available


  241. MASSACCESI M, Dinapoli N, Fuga V, Rupe C, et al
    A predictive nomogram for trismus after radiotherapy for head and neck cancer.
    Radiother Oncol. 2022 Jun 2. pii: S0167-8140(22)04137.
    PubMed     Abstract available


    May 2022
  242. LIU Z, Luo Y, Guo R, Yang B, et al
    Head and Neck Radiotherapy Causes Significant Disruptions of Cochlear Ribbon Synapses and Consequent Sensorineural Hearing Loss.
    Radiother Oncol. 2022 May 28. pii: S0167-8140(22)02279.
    PubMed     Abstract available


  243. ZHAO DW, Fan WJ, Fang XM, Luo YR, et al
    Sparing submandibular gland to alleviating acute xerostomia in patients with nasopharyngeal carcinoma treated with helical tomotherapy: Evaluation by diffusion kurtosis imaging.
    Radiother Oncol. 2022 May 15. pii: S0167-8140(22)00251.
    PubMed     Abstract available


  244. YI-LIANG SHEN E, Hung TM, Tsan DL, Cheng NM, et al
    Utilization of the lymph node-to-primary tumor ratio of PET standardized uptake value and circulating epstein-barr virus DNA to predict distant metastasis in nasopharyngeal carcinoma.
    Radiother Oncol. 2022 May 11. pii: S0167-8140(22)00240.
    PubMed     Abstract available


    April 2022
  245. ZHAO Y, Liao X, Wang Y, Lan W, et al
    Level Ib CTV delineation in nasopharyngeal carcinoma based on lymph node distribution and topographic anatomy.
    Radiother Oncol. 2022 Apr 29. pii: S0167-8140(22)00232.
    PubMed     Abstract available


  246. DOHOPOLSKI M, Wang K, Morgan H, Sher D, et al
    Predicting the need for aggressive nutritional supplementation in head and neck cancer patients receiving radiation therapy.
    Radiother Oncol. 2022 Apr 21. pii: S0167-8140(22)00224.
    PubMed     Abstract available


  247. SHEN H, Yin J, Niu R, Lian Y, et al
    Development and validation of a radiomic nomogram to compare the survival benefit of induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy in locoregionally advanced nasopharyngeal carc
    Radiother Oncol. 2022 Apr 21. pii: S0167-8140(22)00222.
    PubMed     Abstract available


  248. LEE BM, Lee CG
    Significance of mid-radiotherapy 18F-fluorodeoxyglucose positron emission tomography/computed tomography in esophageal cancer.
    Radiother Oncol. 2022 Apr 18. pii: S0167-8140(22)00191.
    PubMed     Abstract available


  249. WELZ S, Paulsen F, Pfannenberg C, Reimold M, et al
    Dose escalation to hypoxic subvolumes in head and neck cancer: A randomized phase II study using dynamic [(18)F]FMISO PET/CT.
    Radiother Oncol. 2022 Apr 5. pii: S0167-8140(22)00170.
    PubMed     Abstract available


  250. JENSEN KH, Vogelius IR, Bernsdorf M, Gothelf A, et al
    Early non-cancer mortality risk prediction after curative-intent radiotherapy or chemoradiotherapy for head and neck squamous cell carcinoma.
    Radiother Oncol. 2022 Apr 5. pii: S0167-8140(22)00169.
    PubMed     Abstract available


  251. LUDWIG R, Hoffmann JM, Pouymayou B, Dappen MB, et al
    Detailed patient-individual reporting of lymph node involvement in oropharyngeal squamous cell carcinoma with an online interface.
    Radiother Oncol. 2022;169:1-7.
    PubMed     Abstract available


    March 2022
  252. YUE M, Xue X, Wang Z, Lambo RL, et al
    Dose prediction via distance-guided deep learning: initial development for nasopharyngeal carcinoma radiotherapy.
    Radiother Oncol. 2022 Mar 26. pii: S0167-8140(22)00150.
    PubMed     Abstract available


  253. BORDERIAS-VILLARROEL E, Taasti V, Van Elmpt W, Teruel-Rivas S, et al
    Evaluation of the clinical value of automatic online dose restoration for adaptive proton therapy of head and neck cancer.
    Radiother Oncol. 2022 Mar 25. pii: S0167-8140(22)00149.
    PubMed     Abstract available


  254. KARAVOLIA E, van Rijn-Dekker MI, Van den Bosch L, van den Hoek JGM, et al
    Impact of sarcopenia on acute radiation-induced toxicity in head and neck cancer patients.
    Radiother Oncol. 2022 Mar 15. pii: S0167-8140(22)00145.
    PubMed     Abstract available


  255. ZHOU X, Wang W, Zhou C, Zhu J, et al
    Long-term outcomes of replanning during intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma: An updated and expanded retrospective analysis.
    Radiother Oncol. 2022 Mar 11. pii: S0167-8140(22)00132.
    PubMed     Abstract available


  256. HUANG CC, Lai YR, Chiu WC, Fang FM, et al
    Concurrent chemoradiation therapy is associated with an accelerated risk of cardiovascular autonomic dysfunction in patients with nasopharyngeal carcinoma: A 9-year prospective follow-up study.
    Radiother Oncol. 2022 Mar 11. pii: S0167-8140(22)00129.
    PubMed     Abstract available


  257. CHOW R, Simone CB 2nd
    Radiation induced lymphopenia in head and neck cancer: The importance of rigorous statistical analysis, radiation field size, and treatment modality.
    Radiother Oncol. 2022 Mar 10. pii: S0167-8140(22)00112.
    PubMed    


  258. DAI D, Tian Q, Shui Y, Li J, et al
    Response to "Radiation induced lymphopenia in head and neck cancer: The importance of rigorous statistical analysis, radiation field size, and treatment modality".
    Radiother Oncol. 2022 Mar 10. pii: S0167-8140(22)00109.
    PubMed    


  259. NACHANKAR A, Musha A, Kubo N, Kawamura H, et al
    Dosimetric analysis of intraocular hemorrhage in nonsquamous head and neck cancers treated with carbon-ion radiotherapy.
    Radiother Oncol. 2022 Mar 4. pii: S0167-8140(22)00118.
    PubMed     Abstract available


  260. GORPHE P, Classe M, Ammari S, Garcia G, et al
    Patterns of disease events and causes of death in patients with HPV-positive versus HPV-negative oropharyngeal carcinoma.
    Radiother Oncol. 2022;168:40-45.
    PubMed     Abstract available


    February 2022
  261. LASKAR SG, Sinha S, Pai DP, Nair D, et al
    Definitive and adjuvant radiation therapy for external auditory canal and temporal bone squamous cell carcinomas: Long term outcomes.
    Radiother Oncol. 2022 Feb 24. pii: S0167-8140(22)00106.
    PubMed     Abstract available


  262. BONOMO P, Desideri I, Mangoni M, Saieva C, et al
    Durvalumab with cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: a phase 1/2 trial.
    Radiother Oncol. 2022 Feb 11. pii: S0167-8140(22)00091.
    PubMed     Abstract available


  263. SCANDURRA D, Meijer TWH, Free J, van den Hoek JGM, et al
    Evaluation of robustly optimised intensity modulated proton therapy for nasopharyngeal carcinoma.
    Radiother Oncol. 2022 Feb 5. pii: S0167-8140(22)00080.
    PubMed     Abstract available


  264. PAN D, Rong X, Zhu Y, Ng WT, et al
    A novel nomogram to predict overall survival in head and neck cancer survivors with radiation-induced brain necrosis.
    Radiother Oncol. 2022 Feb 1. pii: S0167-8140(22)00060.
    PubMed     Abstract available


    January 2022
  265. SUN XS, Zhu MY, Wen DX, Luo DH, et al
    Establishment and validation of a recursive partitioning analysis based prognostic model for guiding re-radiotherapy in local recurrence nasopharyngeal carcinoma patients.
    Radiother Oncol. 2022 Jan 28. pii: S0167-8140(22)00028.
    PubMed     Abstract available


  266. MUNGMUNPUNTIPANTIP R, Wiwanitkit V
    Head and neck cancer diagnoses and faster treatment initiation during COVID-19: correspondence.
    Radiother Oncol. 2022 Jan 28. pii: S0167-8140(22)00026.
    PubMed    


  267. SCHOONBEEK RC, de Jel DVC, van Dijk BAC, Willems SM, et al
    Response to "Head and neck cancer diagnoses and faster treatment initiation during COVID-19: Correspondence".
    Radiother Oncol. 2022 Jan 28. pii: S0167-8140(22)00033.
    PubMed    


  268. CHATTERJEE S, Maulik S, Prasath S, Arun B, et al
    Xerostomia quality of life and resource requirements following parotid sparing adaptive radiotherapy in head and neck cancers: Results of a prospective cohort study (Study ID CTRI/2017/11/010683).
    Radiother Oncol. 2022 Jan 27. pii: S0167-8140(22)00024.
    PubMed     Abstract available


  269. ZECH HB, Berger J, Mansour WY, Nordquist L, et al
    Patient derived ex vivo tissue slice cultures demonstrate a profound DNA double-strand break repair defect in HPV-positive oropharyngeal head and neck cancer.
    Radiother Oncol. 2022 Jan 27. pii: S0167-8140(22)00022.
    PubMed     Abstract available


  270. AL-MAMGANI A, Kessels R, Janssen T, Navran A, et al
    The dosimetric and clinical advantages of the GTV-CTV-PTV margins reduction by 6mm in head and neck squamous cell carcinoma: significant acute and late toxicity reduction.
    Radiother Oncol. 2022 Jan 20. pii: S0167-8140(22)00017.
    PubMed     Abstract available


  271. HE J, Qian L, Gao J
    Comment on ''Photobiomodulation therapy for the prevention of acute radiation dermatitis (RD) in head and neck cancer patients (DERMISHEAD trial)".
    Radiother Oncol. 2022 Jan 19. pii: S0167-8140(22)00005.
    PubMed    


  272. ROBIJNS J, Lodewijckx J, Claes S, Van Bever L, et al
    Response to the Comment on ''Photobiomodulation therapy for the prevention of acute radiation dermatitis (RD) in head and neck cancer patients (DERMISHEAD trial)"by He et al.
    Radiother Oncol. 2022 Jan 19. pii: S0167-8140(22)00006.
    PubMed    


  273. DAI D, Tian Q, Shui Y, Li J, et al
    The impact of radiation induced lymphopenia in the prognosis of head and neck cancer: A systematic review and meta-analysis.
    Radiother Oncol. 2022 Jan 8. pii: S0167-8140(22)00007.
    PubMed     Abstract available


  274. HUANG W, Zhang Q, Wu G, Chen P, et al
    Corrigendum to "DCE-MRI quantitative transport mapping for noninvasively detecting hypoxia inducible factor-1alpha, epidermal growth factor receptor overexpression, and Ki-67 in nasopharyngeal carcinoma patients" [Radiother Oncol (2021) 164:146-154].
    Radiother Oncol. 2022 Jan 7. pii: S0167-8140(21)09059.
    PubMed    


  275. LIU T, Shen BW, Liu LT, Yang ZC, et al
    Impact of salvage radiotherapy on survival of patients with advanced locally recurrent nasopharyngeal carcinoma: Derivation and validation of a predictive model.
    Radiother Oncol. 2022 Jan 5. pii: S0167-8140(21)09094.
    PubMed     Abstract available


  276. FORNER LE, Dieleman FJ, Shaw RJ, Kanatas A, et al
    Hyperbaric oxygen treatment of mandibular osteoradionecrosis: Combined data from the two randomized clinical trials DAHANCA-21 and NWHHT2009-1.
    Radiother Oncol. 2022;166:137-144.
    PubMed     Abstract available


    December 2021
  277. GUO Q, Xiao N, Xu H, Zong J, et al
    Rationality of the international guideline's recommendation regarding selective coverage of level Ib in clinical target volume with nasopharyngeal carcinoma: Results from a real-world series.
    Radiother Oncol. 2021 Dec 29. pii: S0167-8140(21)09081.
    PubMed     Abstract available


  278. TANG SQ, Chen L, Li WF, Chan ATC, et al
    Identifying optimal clinical trial candidates for locoregionally advanced nasopharyngeal carcinoma: Analysis of 9,468 real-world cases and validation by two phase 3 multicentre, randomised controlled trial.
    Radiother Oncol. 2021 Dec 28. pii: S0167-8140(21)09077.
    PubMed     Abstract available


  279. SCHOONBEEK RC, de Jel DVC, van Dijk BAC, Willems SM, et al
    Fewer head and neck cancer diagnoses and faster treatment initiation during COVID-19 in 2020: a nationwide population-based analysis.
    Radiother Oncol. 2021 Dec 13. pii: S0167-8140(21)09049.
    PubMed     Abstract available


  280. MUSHA A, Hirai C, Kitada Y, Tsunoda A, et al
    Relationship between oral mucositis and the oral bacterial count in patients with head and neck cancer undergoing carbon ion radiotherapy: A prospective study.
    Radiother Oncol. 2021 Dec 10. pii: S0167-8140(21)09054.
    PubMed     Abstract available


  281. BEUKEMA JC, de Groot C, Plukker JTM, Vliegenthart R, et al
    Late cardiac toxicity of neo-adjuvant chemoradiation in esophageal cancer survivors: a prospective cross-sectional pilot study.
    Radiother Oncol. 2021 Dec 2. pii: S0167-8140(21)09025.
    PubMed     Abstract available


    November 2021
  282. KUTZ LM, Abel J, Schweizer D, Tribius S, et al
    Quality of life, HPV-status and phase angle predict survival in head and neck cancer patients under (chemo)radiotherapy undergoing nutritional intervention: Results from the prospective randomized HEADNUT-trial.
    Radiother Oncol. 2021 Nov 25. pii: S0167-8140(21)09004.
    PubMed     Abstract available


  283. JIN YN, Yang QQ, Li ZQ, Ou XQ, et al
    Development of a Web-based Prognostic Model to Quantify the Survival Benefit of Cumulative Cisplatin Dose during Concurrent Chemoradiotherapy in Childhood Nasopharyngeal Carcinoma.
    Radiother Oncol. 2021 Nov 25. pii: S0167-8140(21)09008.
    PubMed     Abstract available


  284. NISHIBUCHI I, Murakami Y, Kubo K, Imano N, et al
    Temporal Changes and Risk Factors for Esophageal Stenosis after Salvage Radiotherapy in Superficial Esophageal Cancer following Non-Curative Endoscopic Submucosal Dissection.
    Radiother Oncol. 2021 Nov 25. pii: S0167-8140(21)09007.
    PubMed     Abstract available


  285. PATEL V, Kwok J, Burke M, Urbano TG, et al
    Should the HPV positive oropharyngeal cancer patient be considered for a two-stage dental assessment for their radiation treatment?
    Radiother Oncol. 2021;164:232-235.
    PubMed     Abstract available


  286. GAWRYSZUK A, Bijl HP, van der Schaaf A, Perdok N, et al
    Relationship between videofluoroscopic and subjective (physician- and patient- rated) assessment of late swallowing dysfunction after (chemo) radiation: Results of a prospective observational study.
    Radiother Oncol. 2021;164:253-260.
    PubMed     Abstract available


    October 2021
  287. BROOKER RC, Antczak P, Liloglou T, Risk JM, et al
    Genetic variants associated with mandibular osteoradionecrosis following radiotherapy for head and neck malignancy.
    Radiother Oncol. 2021;165:87-93.
    PubMed     Abstract available


  288. CHIN O, Yu E, O'Sullivan B, Su J, et al
    Prognostic Importance of Radiologic Extranodal Extension in Nasopharyngeal Carcinoma Treated in a Canadian Cohort.
    Radiother Oncol. 2021 Oct 27. pii: S0167-8140(21)08785.
    PubMed     Abstract available


  289. ZHANG ZM, Zhao R, Bao Y, Zhou LX, et al
    A novel technique of endonasopharyngeal ultrasound-guided transnasopharyngeal needle aspiration in the diagnosis of submucosal recurrence of nasopharyngeal carcinoma after chemoradiotherapy.
    Radiother Oncol. 2021 Oct 7. pii: S0167-8140(21)08758.
    PubMed     Abstract available


  290. SHI Z, Zhu X, Ke S, Qiu H, et al
    Survival impact of concurrent chemoradiotherapy for elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma: a propensity score matching and landmark analyses.
    Radiother Oncol. 2021 Oct 7. pii: S0167-8140(21)08754.
    PubMed     Abstract available


  291. YAN A, Hanna A, Wilson TG, Deraniyagala R, et al
    Correlation between tumor voxel dose response matrix and tumor biomarker profile in patients with head and neck squamous cell carcinoma.
    Radiother Oncol. 2021 Oct 4. pii: S0167-8140(21)08748.
    PubMed     Abstract available


  292. KANEHIRA T, van Kranen S, Jansen T, Hamming-Vrieze O, et al
    Comparisons of normal tissue complication probability models derived from planned and delivered dose for head and neck cancer patients.
    Radiother Oncol. 2021 Oct 4. pii: S0167-8140(21)06738.
    PubMed     Abstract available


    September 2021
  293. HUANG W, Zhang Q, Wu G, Pian Chen P, et al
    DCE-MRI quantitative transport mapping for noninvasively detecting hypoxia inducible factor-1alpha, epidermal growth factor receptor overexpression, and Ki-67 in nasopharyngeal carcinoma patients.
    Radiother Oncol. 2021 Sep 27. pii: S0167-8140(21)06739.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Otorhinolaryngology is free of charge.